A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers

PURPOSE: To compare the pharmacokinetic profiles, safety and immunogenicity of proposed bevacizumab biosimilar HLX04 with reference bevacizumab in healthy Chinese males. METHODS: In this double-blind Phase 1 study, healthy volunteers (N = 208) were randomized 1:1:1:1 to a single 3 mg/kg intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaoxue, Qian, Hongjie, Sun, Jixuan, Wu, Min, Yu, Chen, Ding, Yanhua, Zhang, Xiaodi, Chai, Katherine, Li, Xiaojiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316231/
https://www.ncbi.nlm.nih.gov/pubmed/34086067
http://dx.doi.org/10.1007/s00280-021-04297-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8316231/
https://www.ncbi.nlm.nih.gov/pubmed/34086067
http://dx.doi.org/10.1007/s00280-021-04297-z

Ejemplares similares